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Research Correspondence

Single Exhaled Breath Metabolomic
Analysis Identiﬁes Unique Breathprint in
Patients With Acute Decompensated Heart Failure
To the Editor: Acute decompensated heart failure (ADHF) is the
most common indication for hospital admission, particularly in the
elderly, yet the identiﬁcation of those with impending decompensation using conventional clinical methods is unreliable and frequently leaves insufﬁcient lag time for therapeutic interventions
(1). Exhaled breath constitutes a complex mixture of hundreds of
volatile organic compounds (VOCs) that could potentially be used
as a safe and noninvasive method of diagnostic and therapeutic
monitoring (2). Previous research studies have identiﬁed elevated
acetone, pentane, and nitric oxide levels in exhaled breath in the
setting of HF correlated with disease severity (3–5). Selected
ion-ﬂow tube mass-spectrometry (SIFT-MS) combines a fast ﬂow
tube technique with quantitative mass spectrometry that is ideally
suited for exhaled breath analysis because it allows for the analysis
of small and humid samples without the need for cumbersome
sample preparation or calibration (6). Scan times are relatively
brief, thus facilitating high throughput and serial comparisons.

Figure 1

Using this technology, we conducted a prospective, single-center
cohort study to assess the feasibility of exhaled breath analysis to
identify patients admitted for ADHF. The study protocol was
approved by the Cleveland Clinic Institutional Review Board. We
recruited 25 consecutive patients admitted with ADHF as their
primary diagnosis (mean left ventricular ejection fraction 27 ⫾
13%, median N-terminal pro–B-type natriuretic peptide level 954
pg/ml) and a control group of 16 subjects admitted with nonADHF cardiovascular diagnoses and who had no clinical evidence
of systemic or venous congestion at the time of enrollment.
Indications for hospitalization in the control group included
unstable angina or non–ST-segment elevation myocardial infarction (6 of 16), conduction disorders (3 of 16), hypertensive
emergency (3 of 16), atrial tachyarrhythmia (2 of 16), or stable angina
(2 of 16). All analyses were performed using JMP Pro 9.0 (SAS
Institute, Cary, North Carolina). As expected, there were signiﬁcant
(p ⬍ 0.01) baseline differences in the frequency of hypertension (54%

Canonical Discriminant Analysis: ADHF Versus Non-HF Controls

Canonical discriminant analysis using 5 selected mass scanning ion peaks was performed in a training cohort of 25 acute decompensated heart failure (ADHF)
subjects (blue) and 16 controls (red). This ADHF “breathprint” was then used to classify an independent validation cohort of 36 ADHF subjects (green) with no
misclassiﬁcations.

vs. 100%) and baseline estimated glomerular ﬁltration rate (68 ⫾ 43
ml/min/1.73 m2 vs. 102 ⫾ 44 ml/min/1.73 m2), which were significantly worse in the ADHF versus control group. Nevertheless, there
were no signiﬁcant differences between groups in age, body mass
index, or several comorbidities (i.e., diabetes mellitus, chronic obstructive pulmonary disease, active smoking) theorized to result in alterations in the exhaled metabolome.
After written informed consent was obtained, exhaled breath
samples were collected within 24 h of hospital admission and
following an 8-h fast and before the administration of morning
pharmacotherapy. Samples were collected after tap water mouth rinse
to minimize and standardize the contribution of the aerodigestive
tract. Patients provided a single exhaled vital capacity into a sterile
mouthpiece while attempting to maintain an exhaled pressure of 15
millibars. All breath analyses were performed within 2 h of collection
using a VOICE200 SIFT-MS instrument (Syft Technologies,
Christchurch, New Zealand). Pre-speciﬁed quantitative assessment of
acetone and pentane was performed using the SIFT-MS technique.
Sample collection was well tolerated even among patients with disease
severity warranting intensive care unit admission and invasive hemodynamic monitoring. Conﬁrming previous reports (3,4), we observed
increased exhaled acetone (median [interquartile range]: 811 [256 to
1974] ppb vs. 187 [115 to 572] ppb, p ⫽ 0.01) and pentane (40 [20
to 74] ppb vs. 22 [14 to 36] ppb, p ⫽ 0.03) levels in ADHF versus
control groups. In addition, mass scanning of ion products for H3O⫹,
O2⫹, and NO⫹ from 14 to 200 atomic mass units was performed, and
stepwise variable selection was used to identify 5 ion peaks that were
incorporated into a canonical discriminant analysis model that successfully distinguished ADHF from control patients (⫺2 log likelihood 0.038; Wilks’ Lambda 0.102 [p ⬍ 0.0001]) (Fig. 1). This
“breathprint” was then tested in an independent validation cohort of
36 consecutive ADHF subjects with identical enrollment criteria to
the derivation cohort. The discriminant analysis model correctly
classiﬁed all subjects with no misclassiﬁcations (Fig. 1).
The exhaled metabolome is a temporally dynamic complex
mixture, and therefore breath analysis is highly susceptible to the
confounding effects of timing and context of sample collection. In
addition, methods of metabolomic data analysis (e.g., data reduction techniques) are still being formalized and will need to be
reﬁned to facilitate reproducibility and generalizability of future
studies. Results of this study are limited by the small sample size,
and larger prospective studies are needed to validate these results.
Nevertheless, our ﬁndings demonstrate the feasibility of single
exhaled breath analysis in ADHF. In addition, we validated the
previously reported alterations in acetone and pentane VOC
concentrations in ADHF, and provided pilot evidence to support
the hypothesis that a unique ADHF breathprint exists using
SIFT-MS technology. Once a speciﬁc VOC or panel of VOCs is
identiﬁed, highly sensitive and speciﬁc solid-state sensors can be
integrated into portable detectors. Like conventionally available
exhaled breath sensors, the promise of this technology lies in the
potential for point-of-care and ambulatory monitoring and screening. Future studies in exhaled breath metabolomics are needed to
accelerate progress in the ﬁeld of cardiovascular medicine.
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Letters to the Editor

Colchicine After Pulmonary Vein
Isolation: Is Inﬂammation the
New Anti-Arrhythmic Target
We have read with interest the study by Deftereos et al. (1) aimed
at testing the role of colchicine in preventing atrial ﬁbrillation (AF)
recurrences in patients with recurrent paroxysmal AF who under-
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